SYNDAX PHARMACEUTICALS INC's ticker is SNDX and the CUSIP is 87164F105. A total of 124 filers reported holding SYNDAX PHARMACEUTICALS INC in Q3 2021. The put-call ratio across all filers is 0.54 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $68,471 | +128.2% | 3,242 | +162.7% | 0.02% | +46.7% |
| Q3 2022 | $30,000 | +36.4% | 1,234 | +9.0% | 0.02% | +7.1% |
| Q2 2022 | $22,000 | -78.6% | 1,132 | -80.9% | 0.01% | -73.1% |
| Q1 2022 | $103,000 | +171.1% | 5,933 | +238.6% | 0.05% | +188.9% |
| Q4 2021 | $38,000 | +26.7% | 1,752 | +10.9% | 0.02% | -5.3% |
| Q3 2021 | $30,000 | +150.0% | 1,580 | +122.8% | 0.02% | +137.5% |
| Q2 2021 | $12,000 | – | 709 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Kynam Capital Management, LP | 3,600,000 | $52,272,000 | 8.55% |
| Foresite Capital Management IV, LLC | 875,000 | $12,705,000 | 7.06% |
| Aisling Capital Management LP | 1,025,000 | $14,883,000 | 6.13% |
| Saturn V Capital Management LP | 807,969 | $11,731,710 | 4.91% |
| Eversept Partners, LP | 2,596,245 | $37,697,477 | 3.19% |
| ACUTA CAPITAL PARTNERS, LLC | 297,035 | $4,312,948 | 2.89% |
| Paradigm Biocapital Advisors LP | 2,390,077 | $34,703,918 | 2.36% |
| DAFNA Capital Management LLC | 458,373 | $6,655,576 | 2.07% |
| SPHERA FUNDS MANAGEMENT LTD. | 773,061 | $11,224,846 | 2.04% |
| PFM Health Sciences, LP | 2,715,235 | $39,425,212 | 1.86% |